ASCO23 - LBA3: OS analysis from the ADAURA trial of adjuvant osimertinib in resected EGFR‐mutate...

Поделиться
HTML-код
  • Опубликовано: 6 сен 2024
  • LBA3: Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‐mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). More info @ www.Oncoletter.ch

Комментарии •